Cipla slips after Qilu Pembrolizumab deal; Morgan Stanley flags crowded field
Cipla slips after Qilu Pembrolizumab deal; Morgan Stanley flags crowded field — Cipla stock trades at ₹1,388, down 0.48% or ₹6.70 from its previous close of ₹1,394.70
The development comes amid broader attention within the sector, with stakeholders following the matter closely as details emerge. Reports suggest the situation is being monitored by the concerned authorities and organisations.
Browse this may have implications for industry players and the public in the coming days. Further updates are expected as new information becomes available.
